Key statistics
On Wednesday, Emergent BioSolutions Inc (EBS:NYQ) closed at 8.77, 118.16% above the 52 week low of 4.02 set on Apr 09, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 8.90 |
|---|---|
| High | 9.03 |
| Low | 8.67 |
| Bid | 8.66 |
| Offer | 8.77 |
| Previous close | 8.92 |
| Average volume | 1.55m |
|---|---|
| Shares outstanding | 51.77m |
| Free float | 50.36m |
| P/E (TTM) | 6.78 |
| Market cap | 454.03m USD |
| EPS (TTM) | 1.29 USD |
Data delayed at least 15 minutes, as of Mar 04 2026 21:00 GMT.
More ▼
- Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors
- Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results
- Emergent BioSolutions Announces New $50 Million Stock Repurchase Program
- Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada’s Leadership in Health Preparedness
- Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks
- Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
- Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness
- Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation
- Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026
- Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa
More ▼
